Of the @ patients experiencing a major bleed , @ ( @ % ) would have been excluded from the Randomized Evaluation of Long-Term Anticoagulation Therapy ( RE-LY ) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for prevention of Stroke and Embolism Trial in Atrial Fibrillation ( ROCKET AF ) clinical trials .